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Bexarotene is an oral retinoid shown to be active against 
the cutaneous manifestations of cutaneous T-cell lym-
phoma (CTCL). Literature on the efficacy, dosing and 
side-effects of bexarotene is sparse. We present here data 
on 37 Finnish patients with CTCL treated with bexaro-
tene during the last 10 years. Bexarotene was equally 
effective as monotherapy or when combined with other 
treatment modalities, resulting in overall responses of 
approximately 75%. Early-stage CTCL responded bet-
ter than advanced-stage CTCL (83% vs. 33%). The 
mean time to observable response was 3 months and the 
mean duration of the response was 21 months. The dose 
of bexarotene was generally lower than recommended 
due to side-effects. Abrupt elevation of liver transamina-
ses, resulting in cessation of treatment, was observed in 4 
(11%) patients. We conclude that the dose of bexarotene 
should be titrated individually to achieve optimal results. 
Maintenance therapy with low-dose bexarotene is a fea-
sible alternative. Key words: cutaneous T-cell lymphoma; 
mycosis fungoides; Sézary syndrome; bexarotene; Fin-
land.
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Primary cutaneous T-cell lymphomas (CTCL) define 
a heterogeneous group of T-cell lymphoproliferative 
disorders originating in the skin. Mycosis fungoides 
(MF) is the most common form, comprising almost half 
of all primary cutaneous lymphomas. MF typically af-
fects older adults (median age at diagnosis 57.5 years), 
and the male:female ratio is 1.8:1 (1). Sézary syndrome 
(SS) is the leukaemic form of CTCL with distinct mole-
cular pathogenesis of MF (2). The treatment algorithm 
of CTCL is based on the stage of the disease (3, 4). The 
tumour-node-metastasis-blood (TNMB)-based staging 
criteria were revised in 2007 (5).
MF has an indolent clinical course and the disease 
progresses slowly. The estimated 5-year survival rate 
is 88% (1). However, in SS the prognosis is poor, the 
5-year survival rate being only 24%. Skin-directed 
therapy (e.g. topical steroids) usually leads to long 
remissions in the early stages (IA–IIA). MF confined 
to the skin is treated with photo-(chemo)-therapy, 
ultraviolet B (UVB) and psoralen plus ultraviolet A 
(PUVA), whereas combination chemotherapy is recom-
mended for systemic CTCL (stage IV). SS is treated 
with extracorporeal photopheresis (ECP), either alone 
or in combination with, e.g. interferon (IFN)-α, or with 
IFN-α alone or in combination with PUVA. Other no-
vel treatment modalities for MF and SS include CD52 
antibody alemtuzumab, histone deacetylase inhibitors 
vorinostat, romidepsin; recombinant fusion protein 
denileukin diftitox, and selective retinoid bexarotene, 
as discussed further in this article (3, 6–9). In highly 
selected cases of MF or SS, bone marrow transplantation 
may be an option (10).
Retinoids belong to the steroid hormone family 
of molecules. They have long been used alone or in 
combination with other therapies for CTCL (11, 12). 
The advantage of retinoids is that they do not have the 
side-effects of immunosuppressive drugs and can be 
administered orally. The biological effects of retinoids 
have been shown to be mediated by the retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs). 
Bexarotene is the first synthetic highly (RXR) selective 
retinoid "rexinoid" that has proven effective, safe and 
well tolerated in refractory CTCL (13). Bexarotene 
was approved by the Food and Drug Administration 
(FDA) in 1999 and was licensed in Europe in 2002 for 
the treatment of advanced stages of CTCL. In Finland, 
we have used bexarotene as a second-line therapy since 
2002. The exact mechanism of action of bexarotene 
is unknown, but it binds to RXR and induces dose-
dependent apoptosis of malignant T lymphocytes (14). 
It does not affect T-regulatory cells, keratinocytes or 
Langerhans’ cells of the skin (15–17). The well-known 
side-effects of bexarotene include hypertriglyceridae-
mia, which requires individual dosing of this drug and 
often a preventative usage of lipid-lowering therapy 
and thyroid hormone replacement, followed by moni-
toring of laboratory parameters. There are only a few 
reports concerning the optimal duration and guidance 
for bexarotene treatment (8, 18, 19).
The aim of this study was to evaluate 10-year bexa-
rotene treatment results and observed unexpected side-
Ten-year Experience of Bexarotene Therapy for Cutaneous T-cell 
Lymphoma in Finland
Liisa VäkEVä, Annamari RANkI and Sonja HAHTOLA
Department of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Included in the theme issue: 
ACNE, RETINOIDS AND LYMPHOMAS
Acta Derm Venereol 2012; 92: 258–263
259Bexarotene in CTCL
effects in CTCL patients treated in our hospital district, 
to determine the optimal schedule for bexarotene treat-
ment, tapering of the dose, and duration of therapy. Also, 
we report on the difference in response rates between 
bexarotene monotherapy and combination with other 
treatment modalities.
PATIENTS AND METHODS
Thirty-seven patients with CTCL treated with bexarotene in 
Helsinki University Central Hospital (HUCH, the Skin and 
Allergy Hospital for the years 2002 to 2012) were examined 
retrospectively. Six patients (16%) were followed up in other 
dermatological clinics after initiation of bexarotene therapy in 
HUCH. The median age of the patients was 60 years (range 
23–87 years). Twenty-one patients (57%) were male and 16 
(43%) female. The diagnosis of CTCL was based on the clini-
cal picture, histopathological characteristics of multiple skin 
biopsies, computed tomography analysis, and T-cell receptor 
gene rearrangement analysis (1, 20). The patients were mainly 
evaluated clinically, but occasionally skin biopsy histology 
was also performed. All patients were classified according to 
the TNMB classification for CTCL staging and the Interna-
tional Society for Cutaneous Lymphomas (ISCL)/European 
Organization of Research and Treatment of Cancer (EORTC) 
classification (5), according to which 26 of the patients (70%) 
had an early-stage MF (stages IA–IIA). Of these early cases, 8 
(31%) were folliculotropic type. Three MF patients (8%) had 
advanced stage disease (stages IIB–IVB), 4 (11%) had Sézary 
syndrome (SS), 1 (3%) had peripheral T-cell lymphoma and 
2 (5%) had subcutaneous panniculitis-like T-cell lymphoma. 
The majority of patients had received other therapies before 
bexarotene administration. Twenty-two patients (59%) recei-
ved UV therapy, mainly PUVA. Eight patients (22%) received 
radiation therapy, and 14 (39%) received systemic therapy, 
for example interferon (IFN), doxorubicin, methotrexate, aci-
tretin, and chlorambucil. Twenty-three patients (64%) had a 
pre-existing chronic illness, typically a cardiovascular disease 
requiring regular medication. On the other hand, 13 patients 
(36%) were otherwise healthy with no regular medication. Ten 
patients (28%) developed another primary malignancy after 
CTCL diagnosis, mainly squamous cell carcinomas of the skin 
and carcinomas of the prostate, mammary glands, and lungs. 
These secondary malignancies were recorded randomly before 
or after bexarotene therapy.
Before starting therapy, the patients were evaluated carefully 
for past medical history, clinical examination, skin biopsy (if 
not taken recently), computed tomography (CT) scan (if not 
performed within the past 12 months), and wide laboratory 
examinations, including full blood cell count, Sézary cell count, 
renal and liver function tests, infection parameters, lipid profile 
and thyroid hormone levels. When starting bexarotene therapy, 
the patients were hospitalized for a short period and monitored 
for the immediate side-effects of bexarotene. The essential 
laboratory parameters were assessed weekly at the beginning 
of the treatment for 4 weeks and monthly thereafter. Clinical 
follow-up was every 2–3 months, and later, in a stable phase 
of the treatment, every 4–6 months.
The daily starting dosage of bexarotene was 300 mg/m2 in 
the earliest years of our bexarotene experience. Since only a 
few patients tolerated it without considerable side-effects, we 
changed to more individual dosing, starting with approximately 
150 mg/m2 daily dose. The dosage is individually altered in 
relation to clinical response and manageable side-effects. In 
the first years of bexarotene use, the patients were followed up 
for laboratory side-effects and a thyroid hormone supplement 
and lipid-lowering agents were started only when needed. 
Thereafter, upon the establishment of bexarotene usage guide-
lines (8), all the patients have been placed on thyroid hormone 
supplement and 2 different lipid-lowering agents, atorvastatin 
and fenofibrate, simultaneously with bexarotene.
In this retrospective study it was not possible to use the 
tumour burden index (TBI) to determine the degree of cuta-
neous involvement. A complete response (CR) to bexarotene 
therapy was defined as no evidence of disease in the skin or 
extracutaneous organs for a minimum of one month. A partial 
response (PR) was defined as a 50% reduction in the area of 
skin lesions for a minimum of one month. The overall response 
category included both PR and CR patients. The patient had 
stable disease (SD), when no significant change in the skin or 
extracutaneous manifestations occurred. Progressive disease 
(PD) was defined as a 50% area increase in skin lesions, and/
or appearance of lymph node, blood, or visceral involvement. 
The time to achieve the response was determined from the 
time of starting bexarotene to the first documentation of either 
CR or PR. The duration of response was determined from the 
first documentation of achieving CR or PR to the subsequent 
documentation of PD.
Adverse effects occurring during bexarotene therapy were 
determined and graded according to National Cancer Institute 
common terminology criteria for adverse events.
RESULTS
Management of bexarotene therapy
The mean age at starting bexarotene treatment was 65 
years (range 37–88 years). All but 3 patients started 
bexarotene treatment as monotherapy. Those 3 patients 
started bexarotene therapy simultaneously with PUVA 
therapy. Nine patients underwent several periods of 
bexarotene treatment because of initial termination of 
the therapy due to side-effects or CR. The dose of bexa-
rotene was first determined based on the body surface 
area, but as experience with the drug increased, the 
dosage was adjusted individually, and it was generally 
lower than the recommended dose. The bexarotene do-
ses varied between 75 and 675 mg/day. Patients were 
treated with bexarotene from 2 to 107 months (mean 
26 months). The overall experience of bexarotene treat-
ment studied is thus 68 patient years.
Majority of cutaneous T-cell lym phoma patients respond 
to bexarotene
A total of 33 patients (75%) achieved an overall respon-
se (either CR or PR; Figs 1 and 2). On the other hand, 11 
patients (25%) did not respond to bexarotene (stable or 
progressive disease). Of the early-stage patients (stages 
IA–IIA), 25 (83%) were responders and 5 (17%) were 
non-responders. Of the advanced-stage patients (stages 
IIB–IVB) only 1 (33%) was a responder and 2 (67%) 
were non-responders. All 4 patients with SS responded 
to bexarotene therapy completely or partially. The 2 
patients with subcutaneous panniculitis-like T-cell 
lymphoma (SPTL) responded partially to bexarotene. 
The mean time to achieve the response to bexarotene 
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treatment was 3 months (range 1–11 months). The 
mean duration of response to therapy was 21 months, 
ranging from 1 to 74 months. Thirteen patients (35%) 
remained on low-dose bexarotene maintenance therapy 
(Figs 3 and 4).
In total, 15 patients (41%) underwent combination 
therapy later in the course of bexarotene treatment. The 
duration of combination therapy was short compared 
with the overall duration of bexarotene therapy. The 
most common concurrent therapy was PUVA for 8 pa-
tients (53%), followed by IFN (6 patients, 40%). Local 
electron beam (EB) and extracorporeal photopheresis 
(ECP) were combined with bexarotene therapy in 2 and 
1 cases, respectively. PUVA therapy was given for a 
2-month period, and IFN for a period of 1 to 9 months 
(mean 3 months). Eleven patients (73%) receiving 
concurrent therapy with bexarotene responded well to 
the combination.
The most common reasons for withdrawal of bexa-
rotene were inefficiency (41%) or side-effects (20%). 
Three patients stopped taking bexarotene after achieving 
CR and one patient after becoming pregnant despite 
precautions. Table SI (available from: http://www.medi-
caljournals.se/acta/content/?doi=10.2340/00015555-
1359) shows in detail the different CTCL subgroups 
and their response, duration of response, combination 
therapy and percentage of maintenance therapy.
Side-effects of bexarotene therapy
In the early phases of bexarotene use in our clinic, 
all patients developed hypertriglyceridaemia and 
hypothyroidism. With increasing clinical experience, 
lipid-lowering therapy and thyroid supplementation 
were routinely administered to patients undergoing 
bexarotene therapy, and, thus, the incidence of these 
side-effects was reduced. Nine patients (24%) reported 
no side-effects when undergoing bexarotene therapy. 
The most common side-effect remained hypertriglyce-
ridaemia, with 19 patients (51%) affected (Table SII; 
available from: http://www.medicaljournals.se/acta/c
ontent/?doi=10.2340/00015555-1359). The grade of 
hypertriglyceridaemia varied between II and IV, the 
highest value being 37 mmol/l. Hypertriglyceridae-
mia was manageable with lipid-lowering therapy and 
for only one patient was it the reason for cessation 
of bexarotene treatment. Hypercholesterolaemia was 
evident in 7 patients (19%), usually manageable with 
Fig. 1. Stage IA mycosis fungoides (a) 
before and (b) after bexarotene treatment 
(complete response). The time-interval 
between (a) and (b) is 3 months in patient 
No. 17.
Fig. 2. Stage IIA mycosis fungoides (a) 
before and (b) after bexarotene treatment 
(partial response). The time-interval 
between (a) and (b) is 6 months in patient 
No. 26.
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lipid-lowering drugs. Five patients (14%) developed 
reversible leucopaenia, usually neutropaenia. Four 
patients (11%) were diagnosed with elevated liver 
transaminases while undergoing bexarotene therapy. 
The transaminases (AST and ALT) were at least 5-fold, 
even over 20-fold elevated, and resulted in termination 
of bexarotene therapy. The levels of liver enzymes 
returned to normal after termination of bexarotene, 
and no hepatitis virus infection or any other known 
cause was involved. For 2 patients, bexarotene was re-
administered with a lowering dose, but rapidly resulted 
in elevation of liver transaminases in one patient.
Since the management algorithm was different at the 
beginning of bexarotene treatment, hypothyroidism 
was diagnosed in only 4 patients (11%). Three of these 
patients had preventatively administered thyroid supp-
lementation and in one patient thyroid supplementation 
was added after starting bexarotene. Anaemia and rash 
(e.g. flush reaction during the first days of bexarotene) 
was observed in 3 patients (8%). Hypoglycaemia (2 
patients), thrombocytopaenia (1 patient) and gastroin-
testinal nausea (1 patient) were rare side-effects. One 
patient developed erysipelas of the lower leg 3 times 
during bexarotene treatment (Table SII).
DISCUSSION
This article summarizes our 10-year experience of 
using bexarotene for treatment of CTCL in Finland. 
Bexarotene is a well-tolerated and effective systemic 
therapy in advanced stages of CTCL. For patients 
bexarotene is user-friendly, convenient and easy to 
administer. It can be used as monotherapy or in com-
bination with other therapies. Our results show that 
bexarotene was equally effective as monotherapy or 
when combined with other treatment modalities. The 
overall response rate as monotherapy was 75% and as 
combination therapy 73%. The response rates are hig-
her than previously reported (13, 21, 22), probably due 
to the larger number of early-stage patients included in 
our series. Of the early-stage CTCL, 83% responded to 
bexarotene, while 17% did not. Of the advanced-stage 
CTCL, 33% responded and 67% did not. In a previous 
British study (22) the response rates were higher in 
advanced-stage disease than in early-stage disease. 
The authors speculate the role-increased tolerance 
of bexarotene side-effects in patients with advanced 
disease. Interestingly, all 4 of our patients with SS 
responded well to bexarotene. Similarly, Abbott et al. 
(22) reported the best response for bexarotene therapy 
Fig. 3. Patient No. 32 with Sézary 
syndrome (SS) (a) before and (b) after 
treatment with bexarotene. The patient 
is now on maintenance treatment with 
75 mg/day (stable disease). This patient 
was initially treated for ultraviolet B 
(UVB)-photosensitivity (and actinic 
reticuloid), which still persists in the neck 
and face area.
Fig. 4. Follicular mycosis fungoides (a) before and (b) after treatment. This 
patient was treated with bexarotene 225 mg and 300 mg  on alternating days 
for 17 months (complete response) in patient No. 1. This patient was nickel 
patch test negative.
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among patients with SS. Bexarotene is known to inhibit 
malignant T-cell chemotaxis in SS, which may be a pos-
sible explanation for a better response (23). Of cases 
of follicular MF, 63% (5/8) responded to bexarotene, 
while 37% (3/8) did not. Previously, a good response 
to bexarotene has been reported in some cases of fol-
liculotropic MF (24). Our 2 SPTL cases first responded 
partially to bexarotene. However, after 3–7 months of 
clinical response, the disease progressed, resulting in 
cessation of bexarotene therapy. Recently, 82% over-
all response rates have been reported for bexarotene 
in SPTL (25). The mean time to achieve a response 
to bexarotene treatment was 3 months in our CTCL 
patients. A large majority of the patients achieved the 
response to bexarotene early, 73% within 3 months. 
For only 27% of patients, the response was achieved 
after 3 months of bexarotene therapy. Similar results 
have been reported previously (22). The duration of the 
response to therapy was a mean of 21 months, ranging 
from 1 to 74 months. This is significantly longer than 
reported previously (22, 26).
CTCL is a group of diseases that has no curative 
treatment. The aim of different therapies is to achieve 
the most durable remission. CTCL patients usually 
survive for many decades, especially those in early-
stage disease. Thus, maintenance treatment must be 
convenient, with minimal side-effects, and it should also 
prolong remission and survival. After targeted therapy, 
we need tools to keep the disease in a non-progressive 
and stable stage (27). Previous studies have shown that 
bexarotene is able to induce and maintain long-lasting 
responses (19). One of our patients with SS has been 
in complete remission with bexarotene monotherapy 
for 74 months, i.e. for longer than 6 years. Ten patients 
(32%) have been in remission for longer than 24 months 
and 22 patients (71%) for longer than 12 months. Our 
experience shows that, after reaching response, bexa-
rotene should be continued for an extended time with 
a minimal effective dose as maintenance therapy. Our 
current practice is to individually titrate the dose to the 
lowest dose that will maintain the response. For the SS 
patient mentioned previously we have been able to keep 
the disease under control with only 75 mg of bexarotene/
day (approximately 45 mg/m2).
In our study we first used higher dosages of bexaro-
tene (300 mg/m2 daily), but with experience and due 
to side-effects, we began with approximately 150 mg/
m2 daily and aimed at individual dosing. This is in line 
with previous reports, in which the dose of bexaro-
tene was titrated to 2–4 tablets (150–300 mg) per day 
(19). We have also found alternate dosing (e.g. 3 and 
4 capsules on alternate days) to be most optimal for 
several patients.
The most common side-effects in the early years of 
using bexarotene were hypertriglyceridaemia and hy-
pothyroidism, which were seen in all our patients. We 
did not pre-treat patients with fenofibrate, which may 
have explained the increased levels of triglycerides. 
Also, at the beginning thyroid supplementation was not 
added simultaneously with bexarotene. With increasing 
clinical experience, lipid-lowering therapy and thyroid 
supplementation were administered routinely to patients 
undergoing bexarotene therapy, and thus the incidence of 
these side-effects was lowered. Hypertriglyceridaemia, 
however, remained the most common side-effect (51%) 
of bexarotene treatment. We reported 4 patients with 
elevated liver transaminases during bexarotene therapy. 
In one patient the increase was detected 2 years after the 
start of therapy. We ruled out all other possible reasons 
(hepatitis, other drugs and toxins) for the increase. The 
levels of liver enzymes returned to normal level after 
termination of bexarotene. To our knowledge, this is the 
first clinical study reporting elevated liver enzymes in 
CTCL patients treated with bexarotene. In one previous 
report elevated liver transaminases were detected, but this 
was in combination with methotrexate (28).
Bexarotene has been used in Finland for 10 years. 
In our experience, it is a safe, effective and reasonably 
well-tolerated drug. This retrospective study revealed 
somewhat higher response rates than previous studies. 
Specific subgroups of CTCL, e.g. SS and follicular MF, 
responded well to bexarotene therapy. 
In conclusion, the dose of bexarotene should be de-
termined individually in order to achieve maximum be-
nefit with manageable side-effects. Bexarotene therapy 
should be continued for long periods as a maintenance 
therapy after achieving CR. Side-effects should be 
monitored carefully with routine laboratory tests. We 
reported notable and recurrent elevation of liver enzy-
mes resulting in cessation of therapy.
The authors declare no conflicts of interest.
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